Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

ClinicalTrials.gov ID: NCT01619332

Public ClinicalTrials.gov record NCT01619332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Following Single and Multiple Ascending Doses in Healthy Subjects and Patients With Type 2 Diabetes

Study identification

NCT ID
NCT01619332
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
220 participants

Conditions and interventions

Interventions

  • LEZ763 Drug
  • Placebo Drug
  • Sitagliptin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2012
Primary completion
Aug 31, 2013
Completion
Aug 31, 2013
Last update posted
Dec 16, 2020

2012 – 2013

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
Novartis Investigative Site Chula Vista California 91910
Novartis Investigative Site Miami Florida 33126
Novartis Investigative Site Orlando Florida 32809
Novartis Investigative Site Cincinnati Ohio 45227
Novartis Investigative Site Knoxville Tennessee 37920
Novartis Investigative Site San Antonio Texas 78209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01619332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2020 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01619332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →